Press releases
These press releases are intended for journalists and analysts/investors.
-
GSK welcomes new Meningococcal B program to help protect those most at risk
GSK welcomed the addition of Meningococcal vaccination for Aboriginal and Torres Strait Islander infants to National Immunisation Program
-
Greater flexibility for Australians with severe asthma with reimbursement of at-home, self-administration delivery of NUCALA® (mepolizumab)
GSK announced that a new pre-filled pen for the self-administration of its targeted therapy for severe eosinophilic asthma patients
-
GSK Australia reports 2019 results (excluding Consumer Healthcare) to ASIC
GSK has reported its 2019 results to the Australian Securities and Investment Commission
-
GSK Australia now holds the marketing authorisation for Zejula (niraparib) for ovarian cancer
GSK now holds the marketing authorisation for Zejula (niraparib) for ovarian cancer
-
Bushfire crisis response from GSK Australia
We are all deeply saddened at the devastation caused by the Australian bushfires and the impact on people and wildlife
-
Australian researcher uncovering keys to malaria elimination receives major research award
Professor Brendan Crabb wins 2019 GSK Award for Research Excellence
-
GSK Australia launches Spectrum: resource group for LGBT+ employees and straight allies
The global GSK employee resource group for LGBTQI employees and their straight allies
-
Important update for health care professionals re: expiry date of Priorix, our measles, mumps and rubella vaccine
GSK would like to provide the following information to ensure there is no confusion in relation to the expiration date of Priorix
-
Andrew Jenkin to Lead new GSK Consumer Healthcare Joint Venture in ANZ
Andrew Jenkin has been appointed General Manager GSK Consumer Healthcare, ANZ
-
New once-daily treatment option reimbursed for patients with asthma
ARNUITY ELLIPTA (fluticasone furoate), once-daily maintenance therapy for asthma reimbursed by the PBS in Australia
-
Policy debate needed to ensure Australia remains a global leader in public access to life saving vaccines
Australia’s National Immunisation Program (NIP) is one of the world’s best, achieving some of the highest vaccination rates in the world
-
GSK statement on ACCC Federal Court judgment
We are pleased with today’s decision in relation to the revised Voltaren Osteo Gel 1% packaging
-
GSK Australia reports 2018 results to ASIC
GSK has reported its 2018 results to the Australian Securities and Investment Commission (ASIC)
-
2019 GSK Award for Research Excellence open for nominations
Nominations for the 2019 GSK Award for Research Excellence are now open and close at midnight on 9 June 2019
-
Experts highlight impact on life after meningococcal disease for Australian survivors
Health experts and survivors have come together for World Meningitis Day to draw attention to the potential lifelong impact meningococcal
-
GSK puts Australian researchers on Discovery Fast Track
GSK will provide access to its expertise in research, platform technologies and compounds to researchers from Monash University
-
Christi Kelsey appointed General Manager, Australia Pharmaceuticals
GSK Australia announced today that Christi Kelsey has been appointed General Manager, succeeding Anne Belcher
-
Parents’ confusion about meningococcal strains and vaccines may leave Australian children and adolescents at risk
New research confirms that poor understanding of meningococcal disease and its different strains means the majority of Australian children
-
Anne Belcher to leave GSK Australia
General Manager to take up role within GSK in United States
-
Australian researchers revolutionising melanoma treatment receive major research award
Professor Georgina Long and Professor Richard Scolyer win GSK Award for Research Excellence 2018
